The best-studied supplement for macular degeneration is the AREDS2 formula, a specific combination of vitamins and minerals shown to reduce the risk of progressing from intermediate to advanced age-related macular degeneration (AMD) by about 25%. No other supplement comes close to this level of clinical evidence. But the formula only helps at certain stages of the disease, and knowing whether it applies to you matters as much as knowing what’s in it.
What’s in the AREDS2 Formula
AREDS2 stands for Age-Related Eye Disease Study 2, a major clinical trial run by the National Eye Institute. The formula that came out of it contains five ingredients: vitamin C (500 mg), vitamin E (400 IU), lutein (10 mg), zeaxanthin (2 mg), zinc (80 mg), and copper (2 mg). Copper is included specifically to prevent a deficiency that high-dose zinc can cause.
This formula is an update to the original AREDS formula from 2001, which contained beta-carotene instead of lutein and zeaxanthin. The swap matters. A 10-year follow-up published by the American Academy of Ophthalmology found that former smokers who took the beta-carotene version nearly doubled their risk of lung cancer. Those who took the lutein/zeaxanthin version had no increased cancer risk. On top of being safer, lutein and zeaxanthin also appeared to slightly lower the risk of progressing to late AMD compared to beta-carotene. If you see an eye supplement that still lists beta-carotene, skip it.
Who Actually Benefits
AREDS2 supplements are not for everyone with macular degeneration. They help in two specific situations: if you have intermediate AMD in one or both eyes, or if you have late AMD in only one eye (the supplement helps protect the other eye). Outside those windows, the evidence doesn’t support using them.
If you have early AMD, AREDS2 will not prevent it from becoming intermediate. If you already have late AMD in both eyes, the supplements probably won’t help either. The 25% risk reduction and the 19% reduction in central vision loss found in the original trial applied specifically to people at high risk of progressing, meaning those in the intermediate stage or with advanced disease in one eye only.
The Zinc Dose Question
The 80 mg zinc dose in the original AREDS formula is high, roughly five to eight times the recommended daily intake. Some people experience stomach upset at that level. The AREDS2 trial tested whether a lower 25 mg dose would work just as well, and researchers found no difference in effectiveness between the two doses.
There’s a catch, though. The AREDS2 trial didn’t include a placebo group, so the 80 mg dose from the original placebo-controlled AREDS trial remains the “gold standard” in the eyes of the National Eye Institute. In practice, many eye care providers are comfortable with the lower dose, especially for patients who have digestive side effects. Both doses are available in commercial AREDS2 formulations.
Genetics May Change the Equation
One of the more surprising findings in AMD research involves genetics. A study published in the Proceedings of the National Academy of Sciences found that the AREDS formula’s benefit varies dramatically depending on your genetic profile, specifically two genes called CFH and ARMS2 that influence AMD risk.
People with high ARMS2 risk and low CFH risk saw a 50% reduction in progression to the wet (most damaging) form of AMD when taking the supplement. But people with the opposite pattern, high CFH risk and low ARMS2 risk, actually progressed faster on the supplement than they did on placebo, with nearly triple the rate of progression. The overall 25% benefit seen in the trial is essentially an average that masks very different outcomes for different genetic groups.
Genetic testing for AMD risk genes is available but not yet part of standard care. This remains an area where personalized recommendations could eventually replace the one-size-fits-all approach.
What About Omega-3s?
Fish oil is one of the most commonly asked-about additions to an AMD supplement regimen. The AREDS2 trial tested this directly by adding omega-3 fatty acids (DHA and EPA) to the formula. The result was clear: omega-3 supplements provided no benefit in slowing AMD progression. They didn’t cause harm either, but they added nothing to the existing formula. If you take fish oil for heart health or other reasons, that’s a separate decision, but it won’t help your macular degeneration.
Saffron as an Emerging Option
Saffron is the most promising supplement being studied alongside AREDS2, though the evidence is still in early stages. Multiple clinical trials have tested daily doses of 20 to 50 mg of saffron (or 5 to 15 mg of its active compound, crocin) over periods of 3 to 12 months. Participants with both wet and dry AMD showed improvements in visual sharpness, contrast sensitivity, and retinal function. These benefits held up regardless of genetic risk factors.
A 2025 review described saffron as a safe and tolerable add-on treatment that may improve visual function and delay disease progression. It’s not a replacement for AREDS2, and no major guidelines recommend it yet, but it’s the closest thing to a second evidence-backed supplement for AMD. Saffron supplements are widely available, though quality and dosing vary significantly between brands.
Choosing a Commercial Product
Dozens of brands sell AREDS2-formula supplements. The label should list the exact amounts from the clinical trial: 500 mg vitamin C, 400 IU vitamin E, 10 mg lutein, 2 mg zeaxanthin, zinc (either 80 mg or 25 mg), and 2 mg copper. Some products add extra ingredients like omega-3s, B vitamins, or herbal extracts. None of those additions have been shown to improve outcomes in rigorous trials, so they’re not a reason to pay more.
Lutein and zeaxanthin are fat-soluble carotenoids, meaning your body absorbs them better when there’s some dietary fat present. Taking your supplement with a meal that includes healthy fats (olive oil, nuts, avocado, or even butter on toast) is a simple way to get more out of each dose. Vitamin E is also fat-soluble, so the same principle applies.
Most formulations split the daily dose across two soft gels. Consistency matters more than timing. The clinical trials that demonstrated benefit ran for five years or longer, so this is a long-term commitment, not a short-term fix.